Good morning. Thank you, everybody, for joining us this morning to talk about the newest Alpha DaRT results coming out of our REGAIN study for recurrent glioblastoma. We are thrilled to be here this morning together to discuss the results that were just presented at the annual meeting of the Society for Neuro-Oncology in Philadelphia over the weekend. Today, I'm joined by Uzi Sofer, our CEO, Dr. Robert Den, our Chief Medical Officer, and Dr. Joshua Palmer, who is a Professor of Radiation Oncology at the James at Ohio State University, as well as Principal Investigator of the REGAIN study. Today, what we're going to do is we're going to review the mechanism of the Alpha DaRT in a quick refresher. We'll move into the results that were discussed and released over the weekend, the interim results from the REGAIN trial.
We'll look at a patient-by-patient overview, and then leave time at the end for a summary and for questions and answers. With that, I'll turn it over to my colleague, Dr. Den, to do a quick refresh of the Alpha DaRT mechanism.
Thank you, Raphi, very much. It's a pleasure to be with all of you this morning. I just want to provide a refresher to bring everyone on the same page, understanding exactly how the Alpha DaRT work and what makes it unique. Why do we focus on alpha radiation? Alpha radiation has two major advantages to standard beta or gamma radiation. While all three types of radiation damage the DNA and by which cause cancer cell death, alphas are unique in that they work independently of oxygen, and this is particularly crucial when we think about diseases like recurrent GBM, which is known pathognomonically to have necrosis, meaning that there is areas of lack of oxygen.
The second major advantage that the alpha radiation has versus beta or gamma radiation is that it causes irreparable double-strand DNA breaks at a much higher threshold, which leads to the cells undergoing various forms of cell death. On the safety side, alphas are quite unique in that they can be stopped by something as thin as a sheet of paper. What this means is that we are able to do our procedures safely in standard operating rooms throughout the world. We do not require that physicians doing the procedure wear any protective lead shielding, and so therefore, we have minimized potential barrier to entry or adoption by the physician staff. Furthermore, the alpha particles themselves have a limitation, which is that they have a very narrow range in tissue and can only travel between 40 to 90 microns.
What that means is that if we were to use a source which releases alpha particles directly, we would have no range. In order to overcome this issue, we have designed what we call the Alpha DaRT. DaRT stands for Diffusing Alpha-emitters Radiation Therapy. Essentially what we do is we take a thin titanium seed and we coat it with a radioactive atom, radium-224, which undergoes radioactive decay, and through this decay process, releases its daughter atoms directly into the tumor. These daughter atoms then carry the subsequent alpha decays further and further away from the placement of the seed itself. Here we can see this on a video where we are-
[Presentation]
Is our seed. I want to now show you how we actually deliver the-
[Presentation]
[Presentation]
I have the pleasure now to turn the microphone over to Dr. Palmer to present the interim results that were just recently presented at the SNO Annual Meeting on the REGAIN trial.
Good morning, everyone. Thank you so much. We want to touch base initially on some of the trial design and some of the purpose of the prospective open-label single-arm study. The initial study design was meant for 10 patients, which has been extended to 20. We have currently treated eight patients to date, and we are going to be presenting six patients today that have reached their time to response assessment, with a planned follow-up of 12 months for each patient. The primary endpoint of the study is feasibility, so understanding the deployment of all the planned sources with the planned tumor coverage that exceeds our predefined study safety, and then serious adverse events within 90 days of the procedure. Our secondary endpoints, which we will also be presenting some of this today, is the radiographic tumor response based on RANO 2.0 and overall survival.
Eligibility for these patients, they have to be an IDH wild-type grade four glioma, up to three recurrences, and a tumor size under 3 cm. They cannot have had prior radiation therapy. The majority of these patients, or all of these patients so far to date, have had radiation in field to their area of recurrence. The treatment then includes a stereotactic intratumoral implant of these titanium sources that have been loaded with radium-224, which you have seen is the Alpha DaRT design, image-guided placement using a craniotomy and burr hole. Our interim feasibility, 100% of patients had all planned sources deployed without any unanticipated serious adverse events. Our ability to cover the tumor was, we were able to meet our primary endpoint for these patients. All eight patients continue to be alive at the last time of follow-up, with a median follow-up of approximately seven months.
Our objective response rate was, for all six patients, five complete responses and one partial response, so our overall response rate being 100%. Our survival so far, again, ranges from 3 to 11.6 months. Our best overall response is assessed at the time of sort of a complete response noted on by RANO criteria. This can subsequently sort of change based on the next MRI. The best overall response continues to await confirmation in some patients as the follow-up continues to remain with just one or two MRIs. So far, there have been no recurrences in the site of treatment and one progression in a distant location away from the tumor that was implanted. We are still evaluating the necrosis or suspected necrosis in two patients, but those are asymptomatic on follow-up thus far.
For our primary feasibility, so far we have only one grade three serious adverse event, which was a seizure related with Todd's paralysis, which resolved with rehab and steroids. The patient is back to his original baseline. The recovery so far has been excellent in all patients. Every patient's stay has been under one day in the hospital, and the first month of the radiation delivery, there has been no additional serious adverse events. We have seen, as we have gotten patients closer to six to 12 months, we do see some radiation treatment changes, which is anticipated in these patients in retreatment. This is our plot here, so you can see where patients are in their follow-up, patients one through six.
When we look at the response assessments and the best overall responses, we have plotted here the treatment dates, the best overall response, and what was seen on their follow-up in any recurrence within the treated area. Thus far, which is sort of our most exciting component of the trial thus far, is that patients with a median follow-up of over six months have no local recurrence, which exceeds what we would expect from historical control. When we read the scans, whether it is necrosis or tumor, this is always a little bit challenging, and this is in part also added into RANO, that these patients can oftentimes, if followed for more than six to 12 months, develop treatment changes around a treatment site.
This is true for any radiation treatment that we deliver, and this is in part why subsequent MRIs are used to confirm a response assessment to determine if a tumor is truly either progression or differentiate what is called pseudoprogression from treatment necrosis. We will go through patients' true imaging and clinical course. These are the patients when they were treated and their current areas of follow-up, their age, and baseline characteristics. You can see here that the patients have a range of one to three numbers of recurrences and were diagnosed at different times throughout the sort of disease course, some surviving for several years prior to their next recurrence. But as you can see, their subsequent recurrences were in a much shorter timeline. Go to patient one. This patient developed a complete response at their first one and three-month scans.
This is now 10 months post-radiation therapy. You can see now that based on the MRI and PET imaging, there is a development of a contralateral corpus callosum failure, so a treatment progression outside of the radiation field. The area that has been radiated developed approximately six months post-treatment, small areas of enhancement outside of the original tumor site, so enhancement around the seeds where the tumor was not originally. This has been stable on two subsequent MRIs that now show essentially treatment changes, where it is currently called as radiation treatment necrosis. Patient two underwent his implant and developed radiation necrosis. This is now approximately seven months post-radiation therapy.
His initial one and three-month scan showed a complete response within the treatment area. You can see on this depiction, there is an area of ring enhancement surrounding the seeds with a large area of necrotic debris in the center of the seeds. This patient is still alive without recurrence. This is felt to be a large area of radiation injury around the region of treatment, and the patient is doing well on no additional therapy. This is a patient that was initially felt to be, on his one-month scan, a partial response. You can see on the left panel, there is still enhancement measured on the left-hand side. I will use the mouse here to just point it out. The measured RANO disease here is actually within the seeds.
As you can see on the subsequent scan in October, that area of tumor, the region that we felt was implanted with the seeds, that area has now completely necrosed. There is no evidence of viable tumor in this area. The area that we see enhancing now here and here is at the edges outside of the field and has no additional imaging findings concerning for tumor. This is likely treatment changes developing at the edges. There are, however, additional areas of enhancement that will require additional confirmation on subsequent scans here in sort of the corona radiata or the near sort of the anterior temporal lobe here. The patient is alive. We placed him on a necrosis medication with bevacizumab due to, not pictured here, but off posterolaterally, you can see it better on his original scan here.
This area was within his prior radiated field, had started to develop necrosis even at the time of implant in this location, was felt not to be diseased because this was negative on his original PET scan. This area did develop continued worsening necrosis after treatment and was placed on bevacizumab for necrosis at this site, and so not for the site that was treated because this was felt to be just sort of necrosis within the treatment with no additional edema. Patient four underwent a partial response. The area that was treated here within the central component of the tumor had started to disappear, but because there was still residual enhancement here, this was still measured as a 58% decrease in size from the original tumor.
But on subsequent MRIs, and this is his October MRI, we started to see development of enhancement outside the seeds, which we saw in the previous patients, but now distant to the area of treatment. There was a new area of nodular enhancement, which this patient is undergoing a subsequent biopsy of this distant location to determine if this is a new area of tumor or area of radiation injury from sort of overlap between the prior radiated field and the Alpha DaRT treatment. The patient continues to be alive with no additional therapy. Patient number five, this is one where we implanted this large area on the medial component of the resection cavity. As you can see here at the one-month scan, this area of tumor has essentially completely responded. You can see that the cavity essentially looks like it extends out into the seeds now.
That's because all of this enhancement has disappeared. On subsequent three-month scans, this patient developed a wide area of what we think of as either treatment changes or pseudoprogression. There's a very large area of enhancement throughout this region that's undergoing confirmation scans, MRIs to determine what this is, because it's in sort of the pseudoprogression outside of the field. Patient number six, this is a patient where we performed two separate trajectories to implant this tumor that was an odd shape. You can see that the original pre-implant areas of enhancement here and here. The implant, post-implant imaging, you can see what we see with most of these is the seeds enhance, causing sort of this diffuse infiltrative sort of edema that occurs right around the seeds at the initial kind of one to two-week mark.
At the one-month mark, you can see all that enhancement goes away, and you no longer see the enhancement of the tumor. This patient underwent a complete response at the one-month mark, continues to do well with no symptoms. What does the data show us? The data shows us that all the pre-planned sources and our ability to place sources without causing major harm was in 100% of patients. There were no unanticipated serious adverse events. All eight patients continue to be alive with a median follow-up of approximately seven months, with an overall response rate with five complete and one partial response, and one still with an unconfirmed response that we continue to follow. They're all being evaluated for their necrosis.
So far, all asymptomatic, and as I showed you, one of the patient's necrosis was in an area not within or treated by the Alpha DaRT seeds, but from their original treatment. In two patients, it's a bit too early to tell necrosis from progression, and this will continue to be evaluated on subsequent scans through the rest of the year. As we continue to follow these patients, we now are enrolling up to 20 patients and following to see how durable these responses are. But we are excited about these interim results so far. Thank you.
Great. Thank you so much, Dr. Palmer. Just to remind everybody, this is an incredibly exciting time for Alpha Tau. We have a number of additional milestones coming up, so this is just part of the landscape of data that we're seeing and releasing as we get it. Just to remind you, obviously, looking at our second half of the year has been very busy. We've already finished treating patients in our pancreatic cancer IMPACT study. Of course, now, today, we're discussing the data from the REGAIN trial in glioblastoma. We are targeting a prostate cancer patient to be treated around the end of the year. Then looking at the beginning of next year, we will look for top-line data from the pivotal study in skin from ReSTART, as well as data from IMPACT.
We do have an additional interim look at the GBM data once the first five patients have completed six months in the trial, which should be in Q1 of 2027 as well. It's a really busy time. Obviously, we're incredibly excited by this data, but also looking forward to a number of meaningful milestones coming up in the coming few months. With that, we're going to pause here and take some questions and thank both all of our participants for their involvement. I believe our first question is from Yigal Nochomovitz from Citi. If we can please pass the mic to him.
Hi, this is Juan Kim on for Yigal. Thanks for taking our question. I wanted to ask, can you just clarify the confirmation status of the three newly reported responses and when we should expect the patients' next confirmatory scans? Also, on the dataset, is there a minimum duration of response or follow-up period that you believe would make the N equals 20 data sufficiently mature for regulatory discussions?
Okay. Palmer, you want to handle some of this on the confirmation on the N equals 20? Also, do you want to answer the confirmation element of it, Palmer?
But as I say, we repeat the question, that you want the confirmation scans for the first three or the first six?
The second three.
The second three. The confirmation typically occurs after getting two additional scans. For the second three patients, we would have confirmation of all the responses after the six-month mark, is usually when we would be the most confident in all the responses. That would probably be sometime in early next year.
You want to address the N equals 20, Dr. Den?
Sure. Thank you. We just recently got approval to increase enrollment to 20. We anticipate doing this in a very quick fashion. In terms of data maturity, we are in constant discussion with the agency regarding this. I think we are seeing very, very promising results early on that are making us very excited about this.
All right. I think next we have Lukas Shumway. If you can pass the microphone to him, please. Luca, can you hear us? All right, perhaps we will come back to him. Can we pass the microphone, please, to Jeff Cohen from Ladenburg?
Can you hear me okay?
Yes, we can.
Wonderful. Could you talk about the number of sources delivered, and then maybe give us a sense of MRI versus PET on follow-ups, and then talk about the up to 20 patient enrollment? Will that be all at Ohio State with Dr. Palmer? Thanks for taking our questions.
Great questions. Right now, the study itself is designed for MRIs to be used for assessment, because currently, PET imaging is still regarded as off-label for the majority of our patients. It just got approval for a version of an amino acid PET only in the setting of radiation injury. Right now, at Ohio State, all patients, including on studies, will get PET imaging. That is why for our enrolled patients at Ohio State, we do get off-label approval, and we have studies for doing amino acid PETs. But again, the amino acid PET for us is mostly to adjudicate difficult to decipher necrosis versus tumor. It is a little bit experimental of what that is going to look like for an Alpha DaRT source, just because there will be an intermix of treatment necrosis, infiltrative immune response, and potentially tumor.
All of those things will make that area very difficult to interpret. So we generally do not use the PET imaging to interpret the Alpha DaRT source. That is really based on RANO and MRI because of the difficulty of that region. We are using it for also new, like if there is areas that we are trying to see are true disease or guide a biopsy, we are getting those. But they are not standard for this trial. So other sites likely, or the majority of the rest of the U.S., may or may not add PET imaging. So right now, the standard component of the imaging that we follow and are using for response assessment is typically MRI alone. The rest of the 20 patients are going to be dispersed amongst multiple sites.
We do have a patient that is enrolled that is going to get their implant in December, early December at NYU. Then we are open at Barrow. There will be enrollment at multiple additional sites through the rest of the trial, because the trial itself enrolling at one site would take much longer. So obviously, having now open sites that are credentialed, which does take a little bit of time so that everyone feels familiar and comfortable with everything for the study, should help us enroll this much faster for the next year. So hopefully within the next year.
I think there was one last question about the number of sources we're using in the patients.
Good question. It's typically somewhere between three and five layers, so somewhere between 21 and 30 to 35 sources.
Okay. Great. Thank you. Thank you, Jeff, for the questions.
Thank you.
I think we have Lukas Shumway back, who was waiting previously from Barclays. Can we pass the mic back to him? Lukas? All right. We will come back to him again. In the meantime, why don't we pass the mic over to Yi Chen from H.C. Wainwright.
Hi. Thank you for taking my questions. Can you comment on the patient level baseline prognosis, and what is the appropriate survival benchmark for these patients? And also whether these patients receive other medications during Alpha Tau treatment?
Good question. As a baseline for recurrent GBM, typically the progression-free survival is somewhere on the order of like two to four months, and the overall survival is typically somewhere between six and nine months on average. Majority of patients in standard of care would be getting cycled through lomustine, in the U.S., Avastin, or some can get surgery. Each of these, unfortunately, have not shown superiority over one another, and it's usually based on physician discretion or choice. The standard for the U.S. typically is Avastin, and that's what's been benchmarked in our prospective trial, looking at re-radiation. But even things like re-radiation and Avastin both have not shown a benefit to each other. They're both essentially the same, with a median survival of somewhere around nine months.
If you can, in a study like this, if you're seeing progressions take longer than four to five months, or survival that's closer to a year or more, that's typically a treatment that may be actually having some difference in the disease course.
Got it. A quick follow-up. Can you clarify what exactly is FDA's requirement for submission? Is REGAIN study the only study required for submission, or another study is required?
I am sorry, can you repeat the question? I just did not hear the end of it.
Oh, so just FDA's exact requirement for potential submission for-
Yes.
whether additional study would be needed.
Yeah. Excellent question. We are in, as you know, our product has Breakthrough Device Designation, and we are part of the TAP, Total Product Life Cycle Advisory Program, specifically for this indication. We are having constant discussions with the agency to discuss this exact point. As soon as we have further clarification with discrete steps, we will be happy to inform the community.
That is it.
Thank you very much.
Yeah. Yes, I think that we are still in discussion with the FDA on this topic, but we believe that a certain regulatory pathway for focus group of patient may be available to us after completion of this study. Of course, subject to the results and future discussion with the FDA.
Okay. Thank you.
Great. Thank you, Yi, for the questions. Let's go to Peter Spennemann from Piper.
Hi there. Can you hear me?
Yes, we can. Morning.
Great. Hi, this is Peter on for Allison Bratzel from Piper Sandler. Just a question for Dr. Palmer. What have you learned about the procedure and source placement from the first eight patients, and have any changes or improvements to the delivery approach been needed? Thank you.
That's a great question. I think what we've learned is that the actual procedure itself is quite straightforward. A lot of what is required to do a good implant is just in preparation. There's a lot of really important steps in terms of utilizing the pretreatment, and then we are doing a within 24 to 48-hour MRI to then confirm source placement and tumor size, just because these tumors can sometimes grow or change. We try to get the most updated version of the MRI to confirm sources, and that the implant will still hold integrity. The actual implant themselves goes very quickly. It's under an hour. All sources can be delivered within about 10 to 15 minutes. The overall procedure with the patient getting the burr hole and navigation takes the majority. The actual delivery is quite quick.
What was the second part of your question? I think what we've learned through the trial is that there because obviously this is the first in-human experience using it. We had identified that a couple of patients were a little bit of challenging location. The superficial location turned out to be very challenging just because the sources come out in a radial aspect of a biopsy needle, and so there's some geometric difficulty of placing it with a small burr hole, which is typically a few millimeters. That won't allow the seed to eject into the brain tissue unless you make a larger burr hole. We've learned that by utilizing a different technique in making a slightly larger aperture for the seeds to come out, then you can place them in that location. We've learned some good lessons there.
We also have identified that there's some challenges just in brain anatomy of areas that are close to ventricles or near major blood vessels. We were initially a little bit hesitant or concerned about this because obviously this is our first attempt to try to make sure that it's safe. What we've learned is that you can actually implant some of these locations quite safely, utilizing our planning techniques. Then we've also modified the ability to place seeds in skip locations. As you can imagine, the seeds come out in seven, as they come out radially, they come out in seven sources, but now we can essentially design it so that if there's an area that we're highly concerned about a particular organ at risk, we can place, say, six or five seeds and not place seeds in that location.
Going through the study, we've been able to make updates in our approach and sort of design to essentially implant more patients and do it in a more safe way. So that's a great question.
Thank you, Peter.
Thank you.
Okay, we're going to try one more time with Lukas from Barclays. Lukas, your last chance. Let's see if we can get you on the call. Can we give the mic over to Lukas, please?
Hi, can you hear me now?
Yes, we can. Morning.
Hello? Okay, cool. Sorry about technical issues. Quick question on the patients that are kind of like in this ambiguous stage of you don't know if there's progression. If there's patients that are at that stage when the interim analysis happens, how are those patients going to be handled? Are you going to count them as progression-free or not progressing?
That's for you.
Thank you. Yes. Yeah, so generally, patients, unless they've developed progression, are considered progression-free, and they're censored at the last time of follow-up. That is the standard way trials handle these patients, and that's how we'll handle them in this analysis. But I think one additional point to stress is that we will have the survival analysis, which is agnostic to this point. As Dr. Palmer mentioned, having the PFS and OS both trending very, very strongly above what would be expected based on historical benchmarks shows the strength of the technology and of the current trial.
Yeah, I think from a clinical perspective, I think the use of overall response in these types of trials is very helpful to understand activity. But what we really want to see, and what you're going to probably get further insights as we present the interim and hopefully longer and more mature data, is we want these responses to not only just show that you can make the tumor look gone, but that it's a durable response in the location and changes the disease course. So that's why things like overall survival will be probably the most critical endpoint in a recurrent GBM, just because, and as you've, if you guys have seen the literature, things like Avastin or other medications that we've used in the past can delay progression, but they don't actually improve survival.
Those are treatments that we often use, but because they're not actually changing the disease course, they're very limited in their utility, and that's what is sort of such an unmet need in this space. I think as we follow this, there will be patients that are in this sort of gray zone, and that's just the nature of glioblastoma, that there'll be some forms of pseudoprogression that we follow through multiple time points for confirmation of response versus true progression. But ideally, if we can get an overall local control of tumor and change the course of disease to being only failing separately, because a lot of the challenge of the GBM is that it's not always just a local disease. It's sort of a diffuse in nature disease that could fail even years later in a new area.
This is where if we can show that this is actually impacting survival, giving us good control locally, that's when this would become a crucial technology to then modify to make, could we use this therapy to essentially modify immune therapies or other treatments down the road to help people live longer in some disease courses? But there are patients that, if it is a local-only area, this will be a long-term durable response. But I think that's where we don't want to get I, as a clinician, don't want to get too worried or excited only about, "Hey, look at how many CRs." I think that's great, but we want to see those CRs lead to patients that are living closer to a year or longer. If we see that's the exciting component.
So far, having all these patients alive up to about six months is incredible, because ideally, like you have seen, some of these patients die within three to six months, or the overall median survival is typically nine months. If we exceed that is the excitement. That is something that we will get in the interim result, because that is obviously much easier to adjudicate. We do not have to worry, are we calling something that is not real progression or whatever, because that is a gray area, and I think it is important to think about as you guys are looking through the results.
Great. Thank you. Thank you, Dr. Palmer. Okay, so we have got the analysts, and thank you. Sorry, Lukas, did you have a question there, or did we get it?
No, I was just saying thanks.
Okay, great. Thank you, Lukas, for the questions. I am glad we got the technical issues resolved. I think we have gone through the analysts. We are getting a bunch of questions submitted as well on Q&A here on the right in the Rin form, so thank you, everybody, for the questions. Maybe I will start with one to Uzi. There is a question here about the manufacturing, and as we think about the potential for approvals here and in other indications, do we expect to have manufacturing in commercial quantities available ahead of a potential FDA approval?
Yes, very good question. We anticipate being ready to manufacture commercial quantity of Alpha DaRT treatment from our Hudson, New Hampshire facility by the time we receive the FDA approval for any indication.
Okay. Thank you, Uzi. We are getting additional questions here on the trial and the recruitment. Dr. Den, maybe a question to you. People asking about the timeline expectations for the recruitment of the 20 patients in the study.
Excellent question. So far we have had the patients recruited at Ohio State, but as Dr. Palmer noted, we have other sites open, and we have planned accrual for our first patient at NYU this upcoming month. That will put us close to the halfway benchmark, and I anticipate that accrual will go much quicker, as it typically does for trials on the back half than on the front half. We have other sites that are engaged and interested, and I think the presentation of this data, both here to you, but more importantly for the physicians at the SNO meeting, has really generated a lot of buzz and excitement and a lot of interest across multiple clinical sites.
Thank you. I am getting a couple questions here about the ability to treat patients who have recurrences. If we have treated a patient before, will we be able to treat them again with the Alpha DaRT? Perhaps, Dr. Palmer, you want to start with that one?
Sure. Yes, we are going to be able to on the study for patients that have a localized recurrence outside the field of the original Alpha DaRT implant, we should be able to offer them an additional implant. That is something that down the road, we do want to be able to do.
Anything you want to add, Dr. Den?
Yeah, I'll just add in that this exact point with the agency. I think that the more data that comes out, the more bullish the agency is on the ability to retreat patients, especially in distal areas, as from a radiation perspective, there is no overlap of the radiation fields between one and the other. I think what this really speaks to is a point that Dr. Palmer brought up, I'll just reiterate, is that what we have seen in these first six patients is an alteration in the disease course and a differentiation in terms of the recurrence patterns that we would typically expect to see in this population. We are not seeing recurrence locally. The one patient that did develop a recurrence was distally, which is atypical for this type of disease.
Great. Thank you. We've got a number of questions around the ability of the trial to support a marketing application or an application for marketing approval. I think we've addressed that, right? That we are hopeful, we're discussing this with the FDA, and we believe it could potentially support an application for approval or for marketing authorization. But of course, that will be TBD based on the data that we see and, of course, discussions with the FDA. We have a question here on requirements for the expanded 20-patient trial and any changes to the study in light of the expansion?
No, there were no additional requirements that were necessary for that. We were able to apply and quickly get approval for an expansion of the trial, which will further provide the necessary evidence on both safety and efficacy for this approach.
Sure. Thank you, Dr. Robert Den. We have got a question here about the go-to-market strategy and how we expect to commercialize this once we do get approval, hopefully. Uzi, maybe you want to address that one?
Yes. We are developing a plan. We believe that by targeting a select group of high-volume, high-value centers around the U.S., we can use a focused launch team to accelerate meaningful sales uptake at launch.
Okay, great. Thank you. Trying to think what else we have here. There was a question here about, is the target, I guess, Dr. Palmer, this gets to your comments earlier, is the target to beat nine months survival? Is that the goal here, what you think would be successful?
I think from an efficacy perspective, because obviously this is still sort of an early phase study looking at safety and feasibility. I think from a benchmarking, if there is survival that exceeds nine months, that would be a sort of early mark to show that this is potentially better. But obviously, to really prove a survival benefit, you would need sort of a very large randomized study. But I think in a sort of a smaller safety feasibility study to show a survival that is over nine months median would, like you said, probably be something that would move the needle for us and tell us that this is a very highly competitive therapy for recurrent GBM.
These are the types of therapies, like, if you see such a good survival and control from something in the recurrent setting, because historically, we do not really have studies that show improvements in survival in any randomized trial in recurrent GBM, this would be something that we would want to move early to an upfront setting, theoretically.
Okay. Dr. Palmer, you are getting a bunch of questions here. Did any of the patients that we treated have cancer that was spreading before the treatment?
So, all the patients had to have had recurrence based on the RANO criteria, so they had to have progressive or recurrent disease. So they all did have spreading tumor at the time of entry into the trial. Those are the areas that we choose to implant. To enter into the study, you have to have progressive and recurrent disease.
There's a question here as to whether we have any evidence of an immune-related effect, abscopal effects.
Enhancement.
Could the Right, obviously, the enhancement plays a role in that. There's a question on whether the retained sources could be foci for epileptic effects or some other concerns that we might have there.
Good question. I think from an epilepsy event, I think that's a great question because we did see two patients have a seizure, but I don't think it's due to the seeds. The actual events occurred within about a seven-day window of the procedure, which is common for us in radiation as a radiation-related event. We see this sometimes in high-dose radiosurgery, that when you get a very brisk immune response to a treatment, you could actually cause a lot of cerebral edema that could lead to a seizure, which is what we feel happened in those two individuals. After that, we've premedicated and medicated patients longer on the study, and then we haven't seen those events happen anymore.
There haven't been any additional patients with, say, seizures, and we don't anticipate the seeds themselves should not, once they're dormant, they shouldn't be a focus for seizure, any more than sort of the patient's underlying risk for seizure with a glioblastoma. Then I think what we've highlighted on some of our imaging that you saw, we do think, or at least my sort of look at these patients through time as we watch these patients' imaging develop enhancement, the seeds themselves enhance quite a bit along the surface of the seed. So, you lose the enhancement of the tumor, and you kind of get very little actual sort of radiation-related injury in that first one-month delivery.
But the interesting thing is all the seeds enhance a lot. Our feeling is we are creating sort of this vascular leakiness that is allowing the immune system to swell into the region, which is a lot different than sort of our historical radiosurgery treatments. We do not typically see that amount of sort of local infiltrative chronic inflammation for such a long time. I showed one of the pictures of one of our longer-term survivors with a PET image. That PET low, because it is not high enough to be really like tumor, but there is a low-grade inflammatory signal that you see all along the area of implant, even up to that 10 months post-treatment, which we would argue is probably still this chronic inflammation occurring within the area, even though we do not see a lot of sort of true damage to the normal brain.
But there is this chronic inflammation that appears to happen, and that is something that could be exploited theoretically down the road.
Great. Thank you. I am getting a question here on what defined the patients as unresectable.
Good question. When we talk with these patients, it is oftentimes the symptoms that would occur with the surgery, the morbidity of the surgery. Some of these patients had tumors that were within an eloquent region of the brain, so areas of speech, motor, or sensory locations. The surgeons there, although it is a relatively confined smaller lesion, which is the definition of getting onto the study, so those theoretically could also get surgery. But oftentimes, for these patients, the surgery could lead to a more significant morbidity, and so they will choose the trial over a surgery.
Okay. Couple things, questions I am getting about points you mentioned during the presentation. Maybe I will defer to both of you on this. First of all, can we talk a bit about the, again, to focus a bit on the necrosis that we are seeing, and how common is that? How concerning is that? What does that mean about potential recurrence in the way you normally look at these scans? I will start with Dr. Palmer, please.
I would say clinically, we often see necrosis in a recurrent glioblastoma patient. So, in sort of differentiating necrosis from pseudoprogression, from true progression, is a pretty common clinical entity that we see day-to-day with these patients. A lot of it is because many of these patients will get cycled through multiple treatments. They will be getting cytotoxic chemotherapies, they will be getting re-irradiation, and then surgeries, all of which can cause this sort of injury in the area. Dealing with that after treatment is not uncommon. That happens quite frequently when we do re-irradiation. It is over half of our patients, if followed more than six months, will develop some form of radiation treatment changes in the region. That is, in the U.S., why it is very common for us to utilize Avastin, not necessarily for oncologic reasons, but for necrosis reasons.
We will use it to essentially calm these reactions so it does not develop into severe symptoms. We try to prevent things like high-grade toxicities, which would be like needing surgery or hospitalization. We commonly will watch these patients and then use Avastin to prevent worsening treatment change. That is a pretty common phenomenon. We do see it even on this trial. But I think the key is, are we using it for oncologic purposes, which would be like, do we think this is true progression and the only way to treat them is with Avastin? Or are we going to use this for radiation injury, which is sort of the common utilization in this setting? For now, the two patients that are on Avastin are on it for radiation injury purposes, one completely unrelated to the AlphaDaRT, and then one probably related to the AlphaDaRT.
Dr. Den, anything you want to add?
Yes. I just want to add a couple of points, which is that, number one, we have to put what we're seeing in context. This is recurrent GBM. These patients have had upfront, all have had upfront surgery, upfront cytotoxic chemotherapy, and radiation. Some of them have also had re-irradiation, and now they're coming to our trial. I think the most important aspect to remember is that all of these patients are completely asymptomatic. What we see in oncology in general is that the more we look for things, the more we can find things. Now, whether those things actually manifest in a clinical manner, where the patients will have symptoms, the patients will have bother, or the patient will even note it, is really the crux of symptom management, right?
In this case, we are treating what we see, which is based purely on the MRI findings, but we are not actually seeing patients coming in with symptomatic changes from this areas of necrosis. I think the fact that we're seeing the survival reaching over six months, we're seeing that the progression reaching over four months for the vast majority of these patients that we have so far, and the only reason that it's not longer is just because we don't have as much follow-up on the patients given the timeframe, but that we're seeing, even when we're seeing this radiation necrosis, it is completely asymptomatic. The patients themselves, by and large, are feeling well, doing well, doing their activities of daily living. If you were to ask one of these recurrent GBM patients, "What are their goals?" Right?
I think only second to increase my survival is keep my quality of life where it is, and that's what we are able to achieve here.
That's actually Thank you, Dr. Den. That fits in very nicely with the question we just got, which is maybe to talk a bit about the quality of life of these patients. Dr. Palmer, obviously you're interacting with these patients. Anything you can say about their quality of life after the treatment, before and after the treatment?
Yeah, I think the exciting thing that we've seen is obviously, because we had When we started enrolling, we didn't know what this was going to end up impacting or how powerful this radiation would impact the patients. Even our very first patient was extremely thankful and grateful and actually did amazing for approximately eight to nine months. He started to recur, obviously, in that distant location at 10 months, but the recurrence was very minimally symptomatic. It was in his corpus callosum, so it started to affect some of his immediate recall, but his overall quality of life was excellent. They were going on trips. They were doing all their family activities. He was very much a part of the community, so he was able to continue to do that.
Even with the progression, and after treatment of this progression, he continues to do all those things. I think I'm highlighting him because he's obviously the furthest out, but we've had all of our patients so far continue to do great. I would highlight also the patient that has sort of this potential pseudoprogression had only a partial response. That individual is actually doing really, really well. Even going through the biopsy back with his local team, we were in communication quite a bit, and the patient is still doing all of his daily activities, going out, and still travels around with his wife. We're very happy to see that the majority of our patients, we really haven't had any of our patients' quality of life diminish for longer than just the one patient that got Todd's paralysis who needed rehab.
I would say his quality of life diminished some with the injury from the seizure, but after approximately a month of rehabilitation at home, he was able to get back to his baseline and continues to do quite well. We're very excited to see that the actual quality of life in majority of patients is excellent and is not really harmed by the treatment, but it is also really challenging because we're dealing with a difficult disease, and their quality of life eventually may change due to their tumor progression somewhere else. I think that so far, we're seeing these patients doing better longer than we would anticipate.
Thank you very much. All right, question for Dr. Den here. Can you talk a bit about the trial criteria? Obviously, we started with a 3 cm lesion limit. Is that something we expect to be able to extend, or how do we think about that now?
Yes, I think this is a great question. I think we've learned a lot during the trial. When we start any new trial, especially one where we've not done the procedure before in patients, we want to be conservative in our approach because safety is paramount. What we've seen, at least in two of our screen failures initially, was one in which the depth of where the tumor was from the skull was quite shallow. The second was, as Dr. Palmer alluded to, where there was concern for a vessel covering a partial area within the tumor, next to the tumor, I should say.
We've addressed both of these issues through updates to our device to be able to treat tumors now much more shallow to the skull base, as well as to be able to treat partial arcs, so not treating all 360 degrees around, but actually determining which part we want to avoid. Those adaptions have already been implemented directly into the tumor. In terms of the 3 cm limit, we set that as we had the limit for a single burr hole diameter of 3.2 cm, so we wanted to be under that. Remember, we have the ability to deliver multiple burr holes, so we can put one right next to each other. I anticipate we would be able to then expand the limitation. We've done that just as precedent. We've done that before in our skin studies, as an example.
Great. Thank you very much. Dr. Den, we're also getting a question about brain metastases, the appropriateness or the relevance, and how do we think about that?
We're very interested in brain metastases. As you know, GBM is the most common primary brain tumor. However, the most common cancer that we see in the brain is brain metastasis. We are actively exploring different trial designs specifically for the treatment of brain metastases, as we know that this is a large unmet patient population. I think that the important insight that we can gather is that the side effect and the safety profile that we see in the setting of recurrent GBM is appropriate and applicable to the brain metastasis study. I think even from this trial, we're already seeing the beginning building blocks in terms of the necessary safety for thinking about treatment of brain metastasis, as the normal brain is the same whether or not the lesion is a primary CNS tumor versus a metastasis.
Great. We had a question here, perhaps Dr. Palmer, about the patient population. Did all of them have an initial resection for their primary tumor?
Yes. Each patient had an initial either gross total resection or subtotal resection, so none of the patients were initially biopsy only.
Got it. Okay, great. Thank you. I think we're through the questions now. Anything else we have left? I have another question here about the brain mets. Maybe, Dr. Palmer, you want to say something about brain mets in terms of how you think about it clinically and the relevance of Alpha DaRT there?
Yeah, I think we have a number of challenges with brain metastasis that you could envision Alpha DaRT being kind of helpful or superior potentially to our current standards. One would be in the setting of a recurrent tumor. We don't see this often, but obviously because we treat thousands of brain mets a year, we do get recurrent radiosurgery recurrent tumors. In that situation, those tumors are more resistant to therapy and oftentimes get retreated or surgery. This would be an ideal location for Alpha DaRT to be used. So in a locally recurrent prior radiated area, that would minimize morbidity of having to do either a large craniotomy, or re-irradiation oftentimes carries a large risk of radiation injury. This could potentially overcome that.
I also think potentially in tumors that are over 2 cm, we have a very difficult time controlling those without additional large surgeries and craniotomies. There's a number of patients that can't get a full resection in large areas or unresectable locations. Tumors that are over 2 cm, brain mets could also be a very good population of patients that Alpha DaRT could be utilized for optimal local control.
Great. Thank you. Another one to Dr. Palmer, as we're running short on time here. Can you talk about how complicated the training is in terms of getting on board here with this procedure?
The training is actually relatively straightforward and simple. I think once you get used to the actual applicator and the device, it's very simple because the surgeons are very well-trained in using the biopsy stereotactic procedure technique. Utilizing the actual applicator and injecting the sources is relatively simple short sessions that can be done to train people, and can be easily utilized across different spectrums of patients, both in the community and in academic centers. It's quite simple.
Great. Thank you. Finally, we're getting a question here about whether we've been in touch with regulatory agencies about GBM outside the U.S. Not yet. Not formally yet. For now, we're focusing our discussion on the FDA. Obviously, we're in close contact with a number of regulatory agencies outside the U.S. as well, but those discussions on the GBM side have been informal in the context of other discussions as well. I see we're at time. I know there are questions still coming in, but we called this for 8:30 to 9:30, so we are going to end here. I'm going to thank everybody very much for their time, for their attendance, for their questions. Thank you, of course, to our speakers, to Uzi, Dr. Den, Dr. Palmer. Thank you very much for your time, and we look forward to sharing additional results as the trial continues.
Thank you, everybody. Have a good day.